样式: 排序: IF: - GO 导出 标记为已读
-
Aldosterone and mineralocorticoid receptor signaling as determinants of cardiovascular and renal injury: an extraordinary paradigm shift Kidney Int. Suppl. (IF 5.5) Pub Date : 2022-03-18 Murray Epstein
-
Epidemiology of chronic kidney disease: an update 2022 Kidney Int. Suppl. (IF 5.5) Pub Date : 2022-03-18 Csaba P. Kovesdy
-
Nonepithelial mineralocorticoid receptor activation as a determinant of kidney disease Kidney Int. Suppl. (IF 5.5) Pub Date : 2022-03-18 Toshifumi Nakamura, Sophie Girerd, Frederic Jaisser, Jonatan Barrera-Chimal
-
Mineralocorticoid receptor activation and antagonism in cardiovascular disease: cellular and molecular mechanisms Kidney Int. Suppl. (IF 5.5) Pub Date : 2022-03-18 Johann Bauersachs, Achim Lother
-
Clinical perspective—evolving evidence of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes Kidney Int. Suppl. (IF 5.5) Pub Date : 2022-03-18 Peter Rossing
-
The renin–angiotensin system biomolecular cascade: a 2022 update of newer insights and concepts Kidney Int. Suppl. (IF 5.5) Pub Date : 2022-03-18 Carlos M. Ferrario, Leanne Groban, Hao Wang, Xuming Sun, Jessica L. VonCannon, Kendra N. Wright, Sarfaraz Ahmad
-
The innate immune response, microenvironment proteinases, and the COVID-19 pandemic: pathophysiologic mechanisms and emerging therapeutic targets Kidney Int. Suppl. (IF 5.5) Pub Date : 2022-03-18 Morley D. Hollenberg, Murray Epstein
-
The role of mineralocorticoid receptor activation in kidney inflammation and fibrosis Kidney Int. Suppl. (IF 5.5) Pub Date : 2022-03-18 James M. Luther, Agnes B. Fogo
-
Considerations for the future: current and future treatment paradigms with mineralocorticoid receptor antagonists—unmet needs and underserved patient cohorts Kidney Int. Suppl. (IF 5.5) Pub Date : 2022-03-18 Murray Epstein
-
Understanding distribution and variability in care organization and services for the management of kidney care across world regions Kidney Int. Suppl. (IF 5.5) Pub Date : 2021-05-01 Aminu K. Bello,Ikechi G. Okpechi,Vivekanand Jha,David C.H. Harris,Adeera Levin,David W. Johnson
-
International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in Africa Kidney Int. Suppl. (IF 5.5) Pub Date : 2021-04-12 Fidelis Oguejiofor, Daniel S. Kiggundu, Aminu K. Bello, Charles R. Swanepoel, Gloria Ashuntantang, Vivekanand Jha, David C.H. Harris, Adeera Levin, Marcello Tonelli, Abdou Niang, Nicola Wearne, Mothusi Walter Moloi, Ifeoma Ulasi, Fatiu A. Arogundade, Syed Saad, Deenaz Zaidi, Mohamed A. Osman, Feng Ye, Ikechi G. Okpechi
Despite positive economic forecasts, stable democracies, and reduced regional conflicts since the turn of the century, Africa continues to be afflicted by poverty, poor infrastructure, and a massive burden of communicable diseases such as HIV, malaria, tuberculosis, and diarrheal illnesses. With the rising prevalence of chronic kidney disease and kidney failure worldwide, these factors continue to
-
International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in Eastern and Central Europe Kidney Int. Suppl. (IF 5.5) Pub Date : 2021-04-12 Alicja Dębska-Ślizień, Aminu K. Bello, David W. Johnson, Vivekanand Jha, David C.H. Harris, Adeera Levin, Marcello Tonelli, Syed Saad, Deenaz Zaidi, Mohamed A. Osman, Feng Ye, Maryam Khan, Meaghan Lunney, Ikechi G. Okpechi, Rumeyza Turan Kazancioglu
Provision of adequate kidney care for patients with chronic kidney disease or kidney failure (KF) is costly and requires extensive resources. There is an inequality in the global distribution of wealth and resources needed to provide this care. In this second iteration of the International Society of Nephrology Global Kidney Health Atlas, we present data for countries in Eastern and Central Europe
-
International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in Latin America Kidney Int. Suppl. (IF 5.5) Pub Date : 2021-04-12 Marina Wainstein, Aminu K. Bello, Vivekanand Jha, David C.H. Harris, Adeera Levin, Maria C. Gonzalez-Bedat, Guillermo J. Rosa-Diez, Alejandro Ferreiro Fuentes, Laura Sola, Roberto Pecoits-Filho, Rolando Claure-Del Granado, Magdalena Madero, Mohamed A. Osman, Syed Saad, Deenaz Zaidi, Meaghan Lunney, Feng Ye, Ivor J. Katz, David W. Johnson
Latin America is a region with a widely variable socioeconomic landscape, facing a surge in noncommunicable diseases, including chronic kidney disease and kidney failure, exposing significant limitations in the delivery of care. Despite region-wide efforts to explore and address these limitations, much uncertainty remains as to the capacity, accessibility, and quality of kidney failure care in Latin
-
International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in the Middle East Kidney Int. Suppl. (IF 5.5) Pub Date : 2021-04-12 Atefeh Amouzegar, Ali K. Abu-Alfa, Mona N. Alrukhaimi, Aminu K. Bello, Mohammad A. Ghnaimat, David W. Johnson, Vivekanand Jha, David C.H. Harris, Adeera Levin, Marcello Tonelli, Meaghan Lunney, Syed Saad, Maryam Khan, Deenaz Zaidi, Mohamed A. Osman, Feng Ye, Ikechi G. Okpechi, Shahrzad Ossareh
Kidney failure is the permanent impairment of kidney function associated with increased morbidity, hospitalization, and requirement for kidney replacement therapy. A total of 11 countries in the Middle East region (84.6%) responded to the survey. The prevalence of chronic kidney disease in the region ranged from 5.2% to 10.6%, whereas prevalence of treated kidney failure ranged from 152 to 826 per
-
International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in Newly Independent States and Russia Kidney Int. Suppl. (IF 5.5) Pub Date : 2021-04-12 Elena Zakharova, Abduzhappar Gaipov, Aminu K. Bello, David W. Johnson, Vivekanand Jha, David C.H. Harris, Adeera Levin, Syed Saad, Maryam Khan, Deenaz Zaidi, Mohamed A. Osman, Feng Ye, Meaghan Lunney, Marcello Tonelli, Ikechi G. Okpechi, Alexander Zemchenkov, Irma Tchokhonelidze
The International Society of Nephrology Global Kidney Health Atlas analyzed the current state of kidney care in Newly Independent States and Russia. Our results demonstrated that the Newly Independent States and Russia region was not an exception and showed the same effect of chronic kidney disease on health and its outcomes, facing many difficulties and challenges in terms of improving kidney care
-
International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in North America and the Caribbean Kidney Int. Suppl. (IF 5.5) Pub Date : 2021-04-12 Aminu K. Bello, Mark McIsaac, Ikechi G. Okpechi, David W. Johnson, Vivekanand Jha, David C.H. Harris, Syed Saad, Deenaz Zaidi, Mohamed A. Osman, Feng Ye, Meaghan Lunney, Kailash Jindal, Scott Klarenbach, Kamyar Kalantar-Zadeh, Csaba P. Kovesdy, Rulan S. Parekh, Bhanu Prasad, Maryam Khan, Adeera Levin
The International Society of Nephrology established the Global Kidney Health Atlas project to define the global capacity for kidney replacement therapy and conservative kidney care, and this second iteration was to describe the availability, accessibility, quality, and affordability of kidney failure (KF) care worldwide. This report presents results for the International Society of Nephrology North
-
International Society of Nephrology Global Kidney Health Atlas: structures, organization and services for the management of kidney failure in North and East Asia Kidney Int. Suppl. (IF 5.5) Pub Date : 2021-04-12 Luxia Zhang, Jinwei Wang, Chih-Wei Yang, Sydney Chi-wai Tang, Naoki Kashihara, Yong-soo Kim, Ariunaa Togtokh, Syed Saad, Feng Ye, Maryam Khan, Deenaz Zaidi, Mohamed A. Osman, Meaghan Lunney, Ikechi G. Okpechi, Vivekanand Jha, David C.H. Harris, Adeera Levin, Marcello Tonelli, Ming-hui Zhao
Kidney failure (KF) is a public health problem in all regions of the world. We aim to provide comprehensive information regarding the disease burden of KF and capacity for providing optimal care in the International Society of Nephrology North and East Asia region based on data from the International Society of Nephrology Global Kidney Health Atlas project. Seven of eight jurisdictions participated
-
International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in Oceania and South East Asia Kidney Int. Suppl. (IF 5.5) Pub Date : 2021-04-12 Isabelle Ethier, David W. Johnson, Aminu K. Bello, Feng Ye, Mohamed A. Osman, Adeera Levin, David C.H. Harris, Peter Kerr, Adrian Liew, Muh Geot Wong, Meaghan Lunney, Syed Saad, Deenaz Zaidi, Maryam Khan, Vivekanand Jha, Marcello Tonelli, Ikechi G. Okpechi, Andrea K. Viecelli
Oceania and South East Asia (OSEA) is a socioeconomically, culturally, and ethnically diverse region facing a rising epidemic of noncommunicable diseases, including chronic kidney disease (CKD). The second iteration of the International Society of Nephrology Global Kidney Health Atlas aimed to provide a comprehensive evaluation of kidney care in OSEA. Of the 30 countries/territories in OSEA, 15 participated
-
International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in South Asia Kidney Int. Suppl. (IF 5.5) Pub Date : 2021-04-12 Smita S. Divyaveer, Raja Ramachandran, Manisha Sahay, Dibya Singh Shah, Fazal Akhtar, Aminu K. Bello, Arpana Iyengar, David W. Johnson, David C.H. Harris, Adeera Levin, Meaghan Lunney, Muhibur Rahman, Harun-Ur Rashid, Syed Saad, Deenaz Zaidi, Mohamed A. Osman, Santosh Varughese, Eranga S. Wijewickrama, Vivekanand Jha
Information about disease burden and the available infrastructure and workforce to care for patients with kidney disease was collected for the second edition of the International Society of Nephrology Global Kidney Health Atlas. This paper presents findings for the 8 countries in the South Asia region. The World Bank categorizes Afghanistan and Nepal as low-income; Bangladesh, Bhutan, India, and Pakistan
-
International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in Western Europe Kidney Int. Suppl. (IF 5.5) Pub Date : 2021-04-12 Dearbhla M. Kelly, Hans-Joachim Anders, Aminu K. Bello, Gabriel Choukroun, Rosanna Coppo, Gavin Dreyer, Kai-Uwe Eckardt, David W. Johnson, Vivekanand Jha, David C.H. Harris, Adeera Levin, Meaghan Lunney, Valerie Luyckx, Hans-Peter Marti, Piergiorgio Messa, Thomas F. Mueller, Syed Saad, Benedicte Stengel, Eric Rondeau
Populations in the high-income countries of Western Europe are aging due to increased life expectancy. As the prevalence of diabetes and obesity has increased, so has the burden of kidney failure. To determine the global capacity for kidney replacement therapy and conservative kidney management, the International Society of Nephrology conducted multinational, cross-sectional surveys and published the
-
Global variation in kidney care: national and regional differences in the care and management of patients with kidney failure. Kidney Int. Suppl. (IF 5.5) Pub Date : 2021-04-12 Aminu K Bello,Ikechi G Okpechi,Vivekanand Jha,David C H Harris,Adeera Levin,David W Johnson
-
Anemia management: a historical perspective Kidney Int. Suppl. (IF 5.5) Pub Date : 2021-03-18 Steven Fishbane
-
Hypoxia-inducible factor–prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease Kidney Int. Suppl. (IF 5.5) Pub Date : 2021-03-18 Volker H. Haase
-
Treatment of anemia in difficult-to-manage patients with chronic kidney disease Kidney Int. Suppl. (IF 5.5) Pub Date : 2021-03-18 Ritesh Raichoudhury, Bruce S. Spinowitz
-
Anemia of cardiorenal syndrome Kidney Int. Suppl. (IF 5.5) Pub Date : 2021-03-18 Peter A. McCullough
-
Iron metabolism and management: focus on chronic kidney disease Kidney Int. Suppl. (IF 5.5) Pub Date : 2021-03-18 Anil K. Agarwal
-
Anemia management for home dialysis including the new US public policy initiative Kidney Int. Suppl. (IF 5.5) Pub Date : 2021-03-18 Anjay Rastogi, Edgar V. Lerma
-
The evolving science of anemia management in chronic kidney disease. Kidney Int. Suppl. (IF 5.5) Pub Date : 2021-03-18 Ziad A Massy,Tilman B Drueke
-
The evolving science of anemia management in chronic kidney disease. Kidney Int. Suppl. (IF 5.5) Pub Date : 2021-03-18 Ziad A Massy,Tilman B Drueke
-
Corrigendum to "Tonelli M, Nkunu V, Varghese C, et al. Framework for establishing integrated kidney care programs in low- and middle-income countries" Kidney Int Suppl. 2020;10:e19-e23. Kidney Int. Suppl. (IF 5.5) Pub Date : 2020-12-01 Marcello Tonelli,Victoria Nkunu,Cherian Varghese,Ali K Abu-Alfa,Mona N Alrukhaimi,Bassam Bernieh,Louise Fox,John Gill,David C H Harris,Fan Fan Hou,Philip J O'Connell,Harun Ur Rashid,Abdou Niang,Shahrzad Ossareh,Vladimir Tesar,Elena Zakharova,Chih-Wei Yang
[This corrects the article DOI: 10.1016/j.kisu.2019.11.002.].
-
China Kidney Disease Network (CK-NET) 2016 Annual Data Report. Kidney Int. Suppl. (IF 5.5) Pub Date : 2020-12-01 Luxia Zhang,Ming-Hui Zhao,Li Zuo,Yue Wang,Feng Yu,Hong Zhang,Haibo Wang,
-
The second Global Kidney Health Summit outputs: developing a strategic plan to increase access to integrated end-stage kidney disease care worldwide. Kidney Int. Suppl. (IF 5.5) Pub Date : 2020-02-19 David C H Harris,Simon J Davies,Fredric O Finkelstein,Vivekanand Jha
-
Corrigendum to "Zhang L, Zhao M-H, Zuo L, et al., on behalf of CK-NET Group. China Kidney Disease Network (CK-NET) 2015 Annual Data Report." Kidney Int Suppl. 2019;9:e1-e81. Kidney Int. Suppl. (IF 5.5) Pub Date : 2020-02-19
[This corrects the article DOI: 10.1016/j.kisu.2018.11.001.].
-
Capturing and monitoring global differences in untreated and treated end-stage kidney disease, kidney replacement therapy modality, and outcomes Kidney Int. Suppl. (IF 5.5) Pub Date : 2020-02-19 Roberto Pecoits-Filho, Ikechi G. Okpechi, Jo-Ann Donner, David C.H. Harris, Harith M. Aljubori, Aminu K. Bello, Ezequiel Bellorin-Font, Fergus J. Caskey, Allan Collins, Alfonso M. Cueto-Manzano, John Feehally, Bak Leong Goh, Kitty J. Jager, Masaomi Nangaku, Muhibur Rahman, Manisha Sahay, Abdulkarim Saleh, Laura Sola, David W. Johnson
A large gap between the number of people with end-stage kidney disease (ESKD) who received kidney replacement therapy (KRT) and those who needed it has been recently identified, and it is estimated that approximately one-half to three-quarters of all people with ESKD in the world may have died prematurely because they could not receive KRT. This estimate is aligned with a previous report that estimated
-
Dialysis funding, eligibility, procurement, and protocols in low- and middle-income settings: results from the International Society of Nephrology collection survey Kidney Int. Suppl. (IF 5.5) Pub Date : 2020-02-19 Valerie A. Luyckx, Brendan Smyth, David C.H. Harris, Roberto Pecoits-Filho
Dialysis provisions and end-stage kidney disease (ESKD) care represents an important challenge, particularly in low-resource settings. The purpose of this project was to survey nephrologists from low- and lower middle-income countries about their experiences in the following domains: (i) Dialysis funding and eligibility; (ii) dialysis-procurement mechanisms; (iii) clinical protocols for dialysis; (iv)
-
Framework for establishing integrated kidney care programs in low- and middle-income countries Kidney Int. Suppl. (IF 5.5) Pub Date : 2020-02-19 Marcello Tonelli, Victoria Nkunu, Cherian Varghese, Ali K. Abu-Alfa, Mona N. Alrukhaimi, Louise Fox, John Gill, David C.H. Harris, Fan Fan Hou, Philip J. O’Connell, Harun Ur Rashid, Abdou Niang, Shahrzad Ossareh, Vladimir Tesar, Elena Zakharova, Chih-Wei Yang
Secular increases in the burden of kidney failure is a major challenge for health systems worldwide, especially in low- and middle-income countries (LMICs) due to growing demand for expensive kidney replacement therapies. In LMICs with limited resources, the priority of providing kidney replacement therapies must be weighed against the prevention and treatment of chronic kidney disease, other kidney
-
Global case studies for chronic kidney disease/end-stage kidney disease care Kidney Int. Suppl. (IF 5.5) Pub Date : 2020-02-19 Chih-Wei Yang, David C.H. Harris, Valerie A. Luyckx, Masaomi Nangaku, Fan Fan Hou, Guillermo Garcia Garcia, Hasan Abu-Aisha, Abdou Niang, Laura Sola, Sakarn Bunnag, Somchai Eiam-Ong, Kriang Tungsanga, Marie Richards, Nick Richards, Bak Leong Goh, Gavin Dreyer, Rhys Evans, Henry Mzingajira, Marcello Tonelli
The prevalence of chronic kidney disease and its risk factors is increasing worldwide, and the rapid rise in global need for end-stage kidney disease care is a major challenge for health systems, particularly in low- and middle-income countries. Countries are responding to the challenge of end-stage kidney disease in different ways, with variable provision of the components of a kidney care strategy
-
Challenges for sustainable end-stage kidney disease care in low-middle-income countries: the problem of the workforce Kidney Int. Suppl. (IF 5.5) Pub Date : 2020-02-19 Charles R. Swanepoel, Mignon I. McCulloch, Georgi Abraham, Jo-Ann Donner, Mona N. Alrukhaimi, Peter G. Blake, Sakarn Bunnag, Stefaan Claus, Gavin Dreyer, Mohammad A. Ghnaimat, Fuad M. Ibhais, Adrian Liew, Marla McKnight, Yewondwossen Tadesse Mengistu, Saraladevi Naicker, Abdou Niang, Gregorio T. Obrador, Jeffrey Perl, Fredric O. Finkelstein
Prevention and early detection of kidney diseases in adults and children should be a priority for any government health department. This is particularly pertinent in the low-middle-income countries, mostly in Asia, Africa, Latin America, and the Caribbean, where up to 7 million people die because of lack of end-stage kidney disease treatment. The nephrology workforce (nurses, technicians, and doctors)
-
Development of a framework for minimum and optimal safety and quality standards for hemodialysis and peritoneal dialysis Kidney Int. Suppl. (IF 5.5) Pub Date : 2020-02-19 Laura Sola, Nathan W. Levin, David W. Johnson, Roberto Pecoits-Filho, Harith M. Aljubori, Yuqing Chen, Stefaan Claus, Allan Collins, Brett Cullis, John Feehally, Paul N. Harden, Mohamed H. Hassan, Fuad Ibhais, Kamyar Kalantar-Zadeh, Adeera Levin, Abdulkarim Saleh, Daneil Schneditz, Irma Tchokhonelidze, Fredric O. Finkelstein
Substantial heterogeneity in practice patterns around the world has resulted in wide variations in the quality and type of dialysis care delivered. This is particularly so in countries without universal standards of care and governmental (or other organizational) oversight. Most high-income countries have developed such oversight based on documentation of adherence to standardized, evidence-based guidelines
-
Considerations on equity in management of end-stage kidney disease in low- and middle-income countries Kidney Int. Suppl. (IF 5.5) Pub Date : 2020-02-19 Wim Van Biesen, Vivekanand Jha, Ali K. Abu-Alfa, Sharon P. Andreoli, Gloria Ashuntantang, Bassam Bernieh, Edwina Brown, Yuqing Chen, Rosanna Coppo, Cecile Couchoud, Brett Cullis, Walter Douthat, Felicia U. Eke, Brenda Hemmelgarn, Fan Fan Hou, Nathan W. Levin, Valerie A. Luyckx, Rachael L. Morton, Guillermo Garcia Garcia
Achievement of equity in health requires development of a health system in which everyone has a fair opportunity to attain their full health potential. The current, large country-level variation in the reported incidence and prevalence of treated end-stage kidney disease indicates the existence of system-level inequities. Equitable implementation of kidney replacement therapy (KRT) programs must address
-
Developing the ethical framework of end-stage kidney disease care: from practice to policy Kidney Int. Suppl. (IF 5.5) Pub Date : 2020-02-19 Valerie A. Luyckx, Dominique E. Martin, Mohammed Rafique Moosa, Aminu K. Bello, Ezequiel Bellorin-Font, Tak Mao Chan, Rolando Claure-Del Granado, Walter Douthat, Somchai Eiam-Ong, Felicia U. Eke, Bak Leong Goh, Vivekanand Jha, Evie Kendal, Adrian Liew, Yewondwossen Tadesse Mengistu, Elmi Muller, Ikechi G. Okpechi, Eric Rondeau, Tushar Vachharajani
Ethical issues relating to end-stage kidney disease (ESKD) care are increasingly being discussed by clinicians and ethicists but are still infrequently considered at a policy level or in the education and training of health care professionals. In most lower-income countries, access to kidney replacement therapies such as dialysis is not universal, leading to overt or implicit rationing of resources
-
The role of kidney transplantation as a component of integrated care for chronic kidney disease Kidney Int. Suppl. (IF 5.5) Pub Date : 2020-02-19 Philip J. O'Connell, Mark Brown, Tak Mao Chan, Rolando Claure-Del Granado, Simon J. Davies, Somchai Eiam-Ong, Mohamed H. Hassan, Kamyar Kalantar-Zadeh, Adeera Levin, Dominique E. Martin, Elmi Muller, Shahrzad Ossareh, Irma Tchokhonelidze, Michele Trask, Ahmed Twahir, Anthony J.O. Were, Chih-Wei Yang, Alexander Zemchenkov, Paul N. Harden
Kidney transplant provides superior outcomes to dialysis as a treatment for end-stage kidney disease. Therefore, it is essential that kidney transplantation be part of an integrated treatment and management plan for chronic kidney disease (CKD). Developing an effective national program of transplantation is challenging because of the requirement for kidney donors and the need for a multidisciplinary
-
Supportive care for end-stage kidney disease: an integral part of kidney services across a range of income settings around the world. Kidney Int. Suppl. (IF 5.5) Pub Date : 2020-02-19 Barnaby Hole,Brenda Hemmelgarn,Edwina Brown,Mark Brown,Mignon I McCulloch,Carlos Zuniga,Sharon P Andreoli,Peter G Blake,Cécile Couchoud,Alfonso M Cueto-Manzano,Gavin Dreyer,Guillermo Garcia Garcia,Kitty J Jager,Marla McKnight,Rachael L Morton,Fliss E M Murtagh,Saraladevi Naicker,Gregorio T Obrador,Jeffrey Perl,Muhibur Rahman,Kamal D Shah,Wim Van Biesen,Rachael C Walker,Karen Yeates,Alexander Zemchenkov
A key component of treatment for all people with advanced kidney disease is supportive care, which aims to improve quality of life and can be provided alongside therapies intended to prolong life, such as dialysis. This article addresses the key considerations of supportive care as part of integrated end-stage kidney disease care, with particular attention paid to programs in low- and middle-income
-
Erratum: Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2017;7:1-59. Kidney Int. Suppl. (IF 5.5) Pub Date : 2019-01-27
[This corrects the article DOI: 10.1016/j.kisu.2017.04.001.].
-
Global capacity for clinical research in nephrology: a survey by the International Society of Nephrology. Kidney Int. Suppl. (IF 5.5) Pub Date : 2019-01-25 Ikechi G Okpechi,Mona Alrukhaimi,Gloria E Ashuntantang,Ezequiel Bellorin-Font,Mohammed Benghanem Gharbi,Branko Braam,John Feehally,David C Harris,Vivekanand Jha,Kailash Jindal,David W Johnson,Kamyar Kalantar-Zadeh,Rumeyza Kazancioglu,Adeera Levin,Meaghan Lunney,Timothy Olusegun Olanrewaju,Vlado Perkovic,Jeffrey Perl,Harun Ur Rashid,Eric Rondeau,Babatunde Lawal Salako,Arian Samimi,Laura Sola,Irma Tchokhonelidze
Due to the worldwide rising prevalence of chronic kidney disease (CKD), there is a need to develop strategies through well-designed clinical studies to guide decision making and improve delivery of care to CKD patients. A cross-sectional survey was conducted based on the International Society of Nephrology Global Kidney Health Atlas data. For this study, the survey assessed the capacity of various
-
Global access of patients with kidney disease to health technologies and medications: findings from the Global Kidney Health Atlas project. Kidney Int. Suppl. (IF 5.5) Pub Date : 2019-01-25 Htay Htay,Mona Alrukhaimi,Gloria E Ashuntantang,Aminu K Bello,Ezequiel Bellorin-Font,Mohammed Benghanem Gharbi,Branko Braam,John Feehally,David C Harris,Vivekanand Jha,Kailash Jindal,Kamyar Kalantar-Zadeh,Rumeyza Kazancioglu,Peter G Kerr,Adeera Levin,Meaghan Lunney,Ikechi G Okpechi,Michelle E Olah,Timothy Olusegun Olanrewaju,Mohamed A Osman,Yasin Parpia,Jeffrey Perl,Bilal Qarni,Harun Ur Rashid,Ahmed
Access to essential medications and health products is critical to effective management of kidney disease. Using data from the ISN Global Kidney Health Atlas multinational cross-sectional survey, global access of patients with kidney disease to essential medications and health products was examined. Overall, 125 countries participated, with 118 countries, composing 91.5% of the world's population,
-
Global overview of health systems oversight and financing for kidney care. Kidney Int. Suppl. (IF 5.5) Pub Date : 2019-01-25 Aminu K Bello,Mona Alrukhaimi,Gloria E Ashuntantang,Ezequiel Bellorin-Font,Mohammed Benghanem Gharbi,Branko Braam,John Feehally,David C Harris,Vivekanand Jha,Kailash Jindal,David W Johnson,Kamyar Kalantar-Zadeh,Rumeyza Kazancioglu,Peter G Kerr,Meaghan Lunney,Timothy Olusegun Olanrewaju,Mohamed A Osman,Jeffrey Perl,Harun Ur Rashid,Ahmed Rateb,Eric Rondeau,Aminu Muhammad Sakajiki,Arian Samimi,Laura Sola
Reliable governance and health financing are critical to the abilities of health systems in different countries to sustainably meet the health needs of their peoples, including those with kidney disease. A comprehensive understanding of existing systems and infrastructure is therefore necessary to globally identify gaps in kidney care and prioritize areas for improvement. This multinational, cross-sectional
-
Guidelines, policies, and barriers to kidney care: findings from a global survey. Kidney Int. Suppl. (IF 5.5) Pub Date : 2019-01-25 Meaghan Lunney,Mona Alrukhaimi,Gloria E Ashuntantang,Aminu K Bello,Ezequiel Bellorin-Font,Mohammed Benghanem Gharbi,Vivekanand Jha,David W Johnson,Kamyar Kalantar-Zadeh,Rumeyza Kazancioglu,Michelle E Olah,Timothy Olusegun Olanrewaju,Mohamed A Osman,Yasin Parpia,Jeffrey Perl,Harun Ur Rashid,Ahmed Rateb,Eric Rondeau,Laura Sola,Irma Tchokhonelidze,Marcello Tonelli,Natasha Wiebe,Isaac Wirzba,Chih-Wei Yang
An international survey led by the International Society of Nephrology in 2016 assessed the current capacity of kidney care worldwide. To better understand how governance and leadership guide kidney care, items pertinent to government priority, advocacy, and guidelines, among others, were examined. Of the 116 responding countries, 36% (n = 42) reported CKD as a government health care priority, which
-
Building blocks toward sustainable kidney care around the world: results from a multinational survey by the International Society of Nephrology. Kidney Int. Suppl. (IF 5.5) Pub Date : 2019-01-25 Adeera Levin
-
Novel therapies for diabetic kidney disease. Kidney Int. Suppl. (IF 5.5) Pub Date : 2019-01-25 David Z I Cherney,George L Bakris
Over the past 30 years there have been many complementary therapies developed to achieve glycemic control and have an impact on cardiovascular outcomes, as well as reduce the risk of microvascular disease. The 2 most notable new entries have been the sodium-glucose cotransporter 2 (SGLT2) inhibitors and the glucagon-like peptide-1 (GLP-1) agonists. Both these classes of agents have demonstrated reductions
-
Cardiovascular outcomes in diabetic kidney disease: insights from recent clinical trials. Kidney Int. Suppl. (IF 5.5) Pub Date : 2019-01-25 Natalia A Rocha,Peter A McCullough
The prevalence of type 2 diabetes is catalyzing a pandemic in kidney disease, with ensuing cardiovascular complications. The effort to identify antidiabetic agents capable of promoting benefits that go beyond the bounds of glucose control has produced remarkable outcomes in recent cardiovascular outcomes trials in patients with type 2 diabetes mellitus, many of whom have diabetic kidney disease. Two
-
Diagnosis of diabetic kidney disease: state of the art and future perspective. Kidney Int. Suppl. (IF 5.5) Pub Date : 2019-01-25 Frederik Persson,Peter Rossing
Approximately 20% to 40% of patients with type 1 or type 2 diabetes mellitus develop diabetic kidney disease. This is a clinical syndrome characterized by persistent albuminuria (> 300 mg/24 h, or > 300 mg/g creatinine), a relentless decline in glomerular filtration rate (GFR), raised arterial blood pressure, and enhanced cardiovascular morbidity and mortality. There is a characteristic histopathology
-
New options for the management of chronic hyperkalemia. Kidney Int. Suppl. (IF 5.5) Pub Date : 2019-01-25 Linda Fried,Csaba P Kovesdy,Biff F Palmer
Hyperkalemia is a frequently detected electrolyte abnormality that can cause life-threatening complications. Hyperkalemia is most often the result of intrinsic (decreased glomerular filtration rate; selective reduction in distal tubule secretory function; impaired mineralocorticoid activity; and metabolic disturbances, such as acidemia and hyperglycemia) and extrinsic factors (e.g., drugs, such as
-
New options for the anemia of chronic kidney disease. Kidney Int. Suppl. (IF 5.5) Pub Date : 2019-01-25 Daniel W Coyne,David Goldsmith,Iain C Macdougall
Anemia is a common complication of chronic kidney disease. Use of erythropoiesis-stimulating agents (ESA) has been a mainstay of treatment since 1990. A series of large trials demonstrated that ESAs have serious safety problems, including increasing cardiovascular and thrombotic events, and death. Analyses suggest high pharmacologic doses of ESAs, rather than the highly achieved hemoglobin, may mediate
-
Update on reducing the development of diabetic kidney disease and cardiovascular death in diabetes. Kidney Int. Suppl. (IF 5.5) Pub Date : 2019-01-25 George L Bakris
-
Action plan for optimizing the design of clinical trials in chronic kidney disease. Kidney Int. Suppl. (IF 5.5) Pub Date : 2017-10-01 Vlado Perkovic,Jonathan C Craig,Worawon Chailimpamontree,Caroline S Fox,Guillermo Garcia-Garcia,Mohammed Benghanem Gharbi,Meg J Jardine,Ikechi G Okpechi,Neesh Pannu,Benedicte Stengel,Katherine R Tuttle,Katrin Uhlig,Andrew S Levey
High-quality clinical trials are the cornerstone of evidence-based prevention and treatment of a disease, but nephrology has a strikingly weak base of such trials. Building the evidence base to improve outcomes for people with a kidney disease, therefore, requires both greater quantity and quality of clinical trials. To address these issues, we propose that we aim to enroll 30% of people with chronic
-
The establishment and validation of novel therapeutic targets to retard progression of chronic kidney disease. Kidney Int. Suppl. (IF 5.5) Pub Date : 2017-10-01 Carol Pollock,Anna Zuk,Hans-Joachim Anders,Mohammad Reza Ganji,David W Johnson,Bertram Kasiske,Robyn G Langham,Roberto Pecoits-Filho,Giuseppe Remuzzi,Jerome Rossert,Yusuke Suzuki,Tetsuhiro Tanaka,Robert Walker,Chih-Wei Yang,Joseph V Bonventre
The focus of this article is to define goals and resulting action plans that can be collectively embraced by interested stakeholders to facilitate new therapeutic approaches to mitigate chronic kidney disease progression. The specific goals include identifying druggable targets, increasing the capacity for preclinical and early clinical development, broadening the availability of new therapeutic approaches
-
Complications of chronic kidney disease: current state, knowledge gaps, and strategy for action. Kidney Int. Suppl. (IF 5.5) Pub Date : 2017-10-01 Aminu K Bello,Mona Alrukhaimi,Gloria E Ashuntantang,Shakti Basnet,Ricardo C Rotter,Walter G Douthat,Rumeyza Kazancioglu,Anna Köttgen,Masaomi Nangaku,Neil R Powe,Sarah L White,David C Wheeler,Orson Moe
The International Society of Nephrology has adopted a proactive approach to defining the current state of kidney care and unmet needs through a multifaceted Closing the Gaps initiative. As part of this initiative, the International Society of Nephrology convened a meeting of experts to develop an approach to tackle acute kidney injury and chronic kidney disease (CKD). This manuscript expands on the
-
Closing the gap between evidence and practice in chronic kidney disease. Kidney Int. Suppl. (IF 5.5) Pub Date : 2017-10-01 Meg J Jardine,Bertram Kasiske,Dwomoa Adu,Mona Alrukhaimi,Gloria E Ashuntantang,Shakti Basnet,Worawon Chailimpamontree,Jonathan C Craig,Donal J O'Donoghue,Vlado Perkovic,Neil R Powe,Charlotte J Roberts,Yusuke Suzuki,Tetsuhiro Tanaka,Katrin Uhlig
There are major gaps between our growing knowledge of effective treatments for chronic kidney disease (CKD), and the delivery of evidence-based therapies to populations around the world. Although there remains a need for new, effective therapies, current evidence suggests that many patients with CKD are yet to fully realize the benefits of blood pressure-lowering drugs (with and without reducing proteinuria
-
Strategies to improve monitoring disease progression, assessing cardiovascular risk, and defining prognostic biomarkers in chronic kidney disease. Kidney Int. Suppl. (IF 5.5) Pub Date : 2017-10-01 Michelle J Pena,Peter Stenvinkel,Matthias Kretzler,Dwomoa Adu,Sanjay Kumar Agarwal,Josef Coresh,Harold I Feldman,Agnes B Fogo,Ron T Gansevoort,David C Harris,Vivekanand Jha,Zhi-Hong Liu,Valerie A Luyckx,Ziad A Massy,Ravindra Mehta,Robert G Nelson,Donal J O'Donoghue,Gregorio T Obrador,Charlotte J Roberts,Laura Sola,Ernest K Sumaili,Sajja Tatiyanupanwong,Bernadette Thomas,Andrzej Wiecek,Chirag R Parikh
Chronic kidney disease (CKD) is a major global public health problem with significant gaps in research, care, and policy. In order to mitigate the risks and adverse effects of CKD, the International Society of Nephrology has created a cohesive set of activities to improve the global outcomes of people living with CKD. Improving monitoring of renal disease progression can be done by screening and monitoring